Merck and Ridgeback’s Oral Antiviral Molnupiravir Can Halve COVID-19 Risk of Hospitalisation
Interim Analysis of Phase 3 Study shows Merck and Ridgeback’s investigational oral antiviral Molnupiravir has reduced the risk of hospitalization
Read moreInterim Analysis of Phase 3 Study shows Merck and Ridgeback’s investigational oral antiviral Molnupiravir has reduced the risk of hospitalization
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreReal-world data has shown the Vaxzevria vaccine (formerly AZD1222), co-developed by AstraZeneca, the University of Oxford and its spin-out company,
Read moreThe University of Oxford has commenced a Phase I clinical trial of a novel HIV vaccine candidate with vaccinations underway
Read moreIQVIA™ has launched it’s Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and
Read moreAleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a partnership to advance the early phase clinical development of Aleta’s
Read moreThe award-winning Contract Research Organisation (CRO) Altasciences will initiate a Phase I Study in healthy normal subjects for ST-2427, a
Read moreThe COVID-19 treatment XAV-19, developed by French biotech company XENOTHERA, has started a European clinical trial in partnership with Contract
Read moreBristol Myers Squibb announced positive results from a Phase 3 Trial, which showed that neoadjuvant treatment with three cycles of
Read more